Are large clinical trials in orthopaedic trauma justified?

Sheila Sprague  
*McMaster University*

Paul Tornetta  
*Boston University School of Medicine*

Gerard P. Slobogean  
*University of Maryland, Baltimore*

Nathan N. O’Hara  
*University of Maryland, Baltimore*

Paula McKay  
*McMaster University*

*See next page for additional authors*

Follow this and additional works at: [https://ir.lib.uwo.ca/boneandjointpub](https://ir.lib.uwo.ca/boneandjointpub)

Part of the *Medicine and Health Sciences Commons*

Citation of this paper:
Sprague, Sheila; Tornetta, Paul; Slobogean, Gerard P.; O’Hara, Nathan N.; McKay, Paula; Petrisor, Brad; Jeray, Kyle J.; Schemitsch, Emil H.; Sanders, David; Bhandari, Mohit; Guyatt, Gordon H.; Walter, Stephen; Anglen, Jeff; Bosse, Michael; Liew, Susan; Sancheti, Parag; Tai, Kerry; Heels-Ansdell, Diane; Buckingham, Lisa; Duraikannan, Aravin; Tanner, Stephanie L.; Snider, Rebecca G.; Altman, Douglas; Gandhi, Rajiv; Bischoff, Markus; Della Rocca, Gregory J.; Risteviski, Bill; Rajaratnam, Krishan; Williams, Dale; Denkers, Matthew; Bednar, Drew; Sadler, John; and Kwok, Desmond, "Are large clinical trials in orthopaedic trauma justified?" (2018). *Bone and Joint Institute*. 1064.  
[https://ir.lib.uwo.ca/boneandjointpub/1064](https://ir.lib.uwo.ca/boneandjointpub/1064)
Authors
Sheila Sprague, Paul Tornetta, Gerard P. Slobogean, Nathan N. O'Hara, Paula McKay, Brad Petrisor, Kyle J. Jeray, Emil H. Schemitsch, David Sanders, Mohit Bhandari, Gordon H. Guyatt, Stephen Walter, Jeff Anglen, Michael Bosse, Susan Liew, Parag Sancheti, Kerry Tai, Diane Heels-Ansdell, Lisa Buckingham, Aravin Duraikannan, Stephanie L. Tanner, Rebecca G. Snider, Douglas Altman, Rajiv Gandhi, Markus Bischoff, Gregory J. Della Rocca, Bill Risteviski, Krishan Rajaratnam, Dale Williams, Matthew Denkers, Drew Bednar, John Sadler, and Desmond Kwok

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/boneandjointpub/1064
Are large clinical trials in orthopaedic trauma justified?

Sheila Sprague1,2*, Paul Tornetta III3, Gerard P. Slobogean4, Nathan N. O’Hara4, Paula McKay2, Brad Petrisor1, Kyle J. Jeray5, Emil H. Schemitsch6, David Sanders6, Mohit Bhandari1,2 and on behalf of the FLOW Investigators

Abstract

Background: The objective of this analysis is to evaluate the necessity of large clinical trials using FLOW trial data.

Methods: The FLOW pilot study and definitive trial were factorial trials evaluating the effect of different irrigation solutions and pressures on re-operation. To explore treatment effects over time, we analyzed data from the pilot and definitive trial in increments of 250 patients until the final sample size of 2447 patients was reached. At each increment we calculated the relative risk (RR) and associated 95% confidence interval (CI) for the treatment effect, and compared the results that would have been reported at the smaller enrolments with those seen in the final, adequately powered study.

Results: The pilot study analysis of 89 patients and initial incremental enrolments in the FLOW definitive trial favored low pressure compared to high pressure (RR: 1.50, 95% CI: 0.75–3.04; RR: 1.39, 95% CI: 0.60–3.23, respectively), which is in contradiction to the final enrolment, which found no difference between high and low pressure (RR: 1.04, 95% CI: 0.81–1.33). In the soap versus saline comparison, the FLOW pilot study suggested that re-operation rate was similar in both the soap and saline groups (RR: 0.98, 95% CI: 0.50–1.92), whereas the FLOW definitive trial found that the re-operation rate was higher in the soap treatment arm (RR: 1.28, 95% CI: 1.04–1.57).

Conclusions: Our findings suggest that studies with smaller sample sizes would have led to erroneous conclusions in the management of open fracture wounds.

Trial registration: NCT01069315 (FLOW Pilot Study) Date of Registration: February 17, 2010, NCT00788398 (FLOW Definitive Trial) Date of Registration: November 10, 2008.

Keywords: Large trials, Orthopaedic trial, Sample size, FLOW trial

Background

Large definitive clinical trials in orthopaedic trauma are expensive, challenging, and time consuming to conduct. In times of limited research funding, their value may be called into question as it costs several million dollars to answer one or two clinical questions and results may not be translated into practice for five to eight years following initiation of the trial [1]. However, it is equally important to consider that smaller trials may be inadequately powered to answer clinical questions or have fragility in their results, potentially leading to an over or underestimation of the true treatment effect. Small studies are subject to Beta error, which is to say that no difference is found even though one may exist. While this is considered a less egregious error than a false finding of a difference in treatments, if one treatment is in fact better than another and this is not found due to small sample size, an opportunity to improve patient care is missed.

Previous research has demonstrated that it is not uncommon for the results of highly cited clinical studies published in high impact medical journals to be contradicted by the findings of subsequent studies [2]. Randomized controlled trials (RCTs) are not immune from having their findings contradicted by subsequent studies, with small RCTs being...
at higher risk than larger ones of having their findings contradicted by subsequent trials [2, 3]. The objective of this study is to evaluate the value of one large clinical trial in orthopaedic trauma using data from the FLOW trial.

Methods

This investigation was part of the multi-centre FLOW (Fluid Lavage in Open Fracture Wounds) initiative. As a means of proving feasibility and testing the FLOW protocol, we completed the FLOW pilot study. The FLOW pilot study was a 2 × 2 factorial design which evaluated irrigation solution (soap vs. normal saline) and irrigation pressure (low vs. high) in patients with open fracture wounds. The FLOW pilot study included 89 patients at nine clinical sites in Canada and the United States. The results of the FLOW pilot study (ClinicalTrials.gov number, NCT01069315) informed the development of the FLOW definitive trial (ClinicalTrials.gov number, NCT00788398), which was a multi-center, blinded, randomized controlled trial, using a 2 × 3 factorial design which evaluated irrigation solution (soap vs. normal saline) and irrigation pressure (very low vs. low vs. high) in patients with open fracture wounds [4]. The FLOW definitive trial included 2447 patients across 41 clinical sites in the United States, Canada, Australia, Norway, and India [5]. The primary outcome for the FLOW pilot and definitive studies was re-operation within 12 months of fracture to treat infection or promote wound or fracture healing. Research Ethics Board (REB) Approval for the FLOW pilot and definitive trial was obtained at the coordinating centre (McMaster University) (REB: 05–299 and 08–268) and at each clinical site. All procedures followed were in accordance with ethical standards of the ethics boards.

To evaluate the value of a trial of this size, we analyzed the data from the pilot study and then the definitive trial in increments of 250 patients until the final sample size was reached. Increments of 250 were selected for ease of reporting and to reflect what the findings would have been for a trial of each incremental size. At each increment, we calculated the relative risk (RR) and associated 95% confidence interval (CI) for the treatment effect. We then compared the results that would have been reported at the smaller enrolments with those seen in the final, adequately powered study. All analyses were performed using JMP Version 12.0 (Cary, NC).

Results

In the soap versus saline comparison, data from the FLOW pilot study suggested that a small benefit to irrigation with soap may exist (RR: 0.98, 95% CI: 0.50–1.92, \(p = 0.82\)). However, the wide confidence intervals on each side of the relative risk indicated similar likelihood that soap or saline could be more efficacious. These preliminary results based on a very small sample size were sharply contrasted by the larger definitive FLOW trial which found that the risk of re-operation was higher in the soap treatment arm (RR: 1.28, 95% CI: 1.04–1.57, \(p = 0.02\)) (Fig. 1). The results achieved statistical significance (with the lower confidence interval for the relative risk being greater than one) when 1500 patients were enrolled into the trial \((p = 0.02)\). As expected, the confidence intervals narrowed as the final sample size of 2447 was reached.

The results of all three pressure comparisons demonstrated similar patterns in which the initial increments of patients favored one pressure over another but the final enrolment of 2447 patients found no difference

![Fig. 1](image-url)
between irrigation pressure treatment groups (Figs. 2, 3 and 4). For example, the pilot study analysis of 89 patients favored low pressure compared to high pressure irrigation (RR: 1.50, 95% CI: 0.75–3.04 (\(p = 0.14\)) (Fig. 2). The initial incremental enrolments in the definitive trial also favored low pressure compared to high pressure (e.g., \(n = 250\), RR: 1.39, 95% CI: 0.60–3.23, \(p = 0.48\)). When 750 patients were enrolled into the trial, the difference approached significance with \(p = 0.06\) (RR: 1.55, 95% CI: 0.99–2.41). This is in contradistinction to the final enrolment of 2447 that found no difference between high and low pressure (RR: 1.04, 95% CI: 0.81–1.33, \(p = 0.82\)).

Similarly, the initial increment of 250 patients favored very low pressure over high pressure (RR: 1.10, 95% CI: 0.52–2.36, \(p = 0.83\)) (Fig. 3), and low pressure over very low pressure (RR: 1.26, 95% CI: 0.54–2.98, \(p = 0.63\)) (Fig. 4). However, in both cases, the final enrolment demonstrated no differences between any of the irrigation pressures.

### Discussion

Our findings suggest that both the results of the FLOW pilot study and selecting a smaller sample size for the FLOW definitive trial would have led to erroneous conclusions in the management of open fracture wounds. With regard to the results of one of the major research questions, namely whether irrigation with soap reduced the re-operation rate, the point estimate changes from potentially favoring soap to demonstrating that irrigation with soap is a risk factor for re-operation in the final enrollment increments of the definitive trial. At lower

### Table 1: Pilot Study Patient Enrollment and Event Rates

| N   | % of Total | Number of Centers | Event Rate, % | Relative Risk | 95% CI |
|-----|------------|-------------------|---------------|---------------|--------|
| 250 | 10.2%      | 4                 | 12.4%         | 1.10          | (0.52–2.36) |
| 500 | 20.4%      | 8                 | 12.2%         | 1.21          | (0.70–2.10) |
| 750 | 30.6%      | 10                | 14.2%         | 1.20          | (0.84–1.92) |
| 1000| 40.9%      | 11                | 13.3%         | 1.16          | (0.80–1.68) |
| 1250| 51.1%      | 14                | 14.6%         | 1.08          | (0.79–1.49) |
| 1500| 61.3%      | 16                | 14.4%         | 1.03          | (0.77–1.39) |
| 1750| 71.5%      | 21                | 14.1%         | 0.96          | (0.73–1.27) |
| 2000| 81.7%      | 27                | 14.3%         | 0.98          | (0.76–1.28) |
| 2250| 91.9%      | 33                | 14.2%         | 0.98          | (0.76–1.25) |
| 2447| 100.0%     | 41                | 13.2%         | 0.97          | (0.76–1.24) |

### Figure 2: Effect of high vs. low pressure on FLOW trial patients at different sample sizes

### Figure 3: Effect of high vs. very low pressure on FLOW trial patients at different sample sizes
enrolment increments, comparisons between different pressures initially favored low pressure over both high and very low pressure, and very low pressure over high pressure. However, no differences between any of the irrigation pressures were observed at the final enrolment of 2447 patients. Most notably, at 750 patients, the results came very close to demonstrating a significant difference favoring low pressure over high pressure despite the fact that no significant differences were observed at higher enrolment increments.

When interpreting these results, it is important to consider that we analyzed the data in sequential increments of 250 patients. Since the number of clinical sites and participating surgeons increased with increasing sample size, differences in performance variables between sites and surgeons may have contributed to the observed differences in outcomes. If we had repeated these analyses using randomly selected subsets of patients, the results may have been quite different. However, this approach would not have represented an accurate reflection of the number of centers, participating surgeons, or enrollment timelines typically associated with smaller RCTs.

The sample size for the pilot study \((n = 89)\) was chosen to inform the design of a large definitive trial and demonstrate to large funding agencies that the selected methodology was feasible. We published the results of the FLOW pilot study to generate interest and promote the definitive trial among the orthopaedic trauma community. We did not publish the pilot study results with the goal of changing clinical practice. Had this been our intent, erroneous treatment recommendations would have been made. In contrast, the sample size for the FLOW definitive trial was based upon the previous literature and the opinion of multiple experts [4].

The FLOW study was a factorial study and the advantages of a factorial design over a standard parallel group design include the ability to efficiently investigate a minimum of two interventions and the reduction in the total number of patients needed to assess multiple interventions aimed at achieving the same outcome. If we had not used a factorial study, the sample size for an adequately powered study, using the assumptions described above, comparing soap versus saline would have been 1200 patients (600 patients per treatment arm). Similarly, a separate study comparing high versus low versus very low pressure would have required 2280 patients (760 per treatment arm). Consequently, answering the two research questions in two separate studies would have required 3480 patients, demonstrating the efficiency of a factorial design.

As demonstrated in Figs. 1, 2, 3 and 4, it is evident that the results of the FLOW study appear to stabilize before the final enrolment of 2447 patients. Specifically, in the soap versus saline comparison the results seem to stabilize around 1200 patients, which is consistent with the above sample size calculation. The results for the comparisons between the three irrigating pressures seem to stabilize following the enrolment of approximately 2000 patients. One may question whether we enrolled too many patients into the FLOW trial. The answer is “no” as this stabilization occurred because the overall FLOW study sample size was calculated based upon the three pairwise comparisons for the pressures, however, in the end, the hypothesized differences between pressures were not observed. Had the results of the FLOW trial shown our hypothesized differences, it is possible that this stabilization would not have occurred until closer to the final sample size. In order to explore treatment effects over time, we have analyzed the data from

| N   | % of Total | Number of Centers | Event Rate, % | Relative Risk | 95% CI       |
|-----|------------|------------------|---------------|--------------|-------------|
| 250 | 10.2%      | 4                | 12.4%         | 1.26         | (0.54-2.98) |
| 500 | 20.4%      | 8                | 12.2%         | 1.21         | (0.66-2.67) |
| 750 | 30.6%      | 10               | 14.2%         | 1.22         | (0.76-1.95) |
| 1000| 40.9%      | 11               | 13.3%         | 1.14         | (0.76-1.72) |
| 1250| 51.1%      | 14               | 14.6%         | 1.17         | (0.83-1.66) |
| 1500| 61.3%      | 16               | 14.4%         | 1.08         | (0.79-1.47) |
| 1750| 71.5%      | 21               | 14.1%         | 1.12         | (0.85-1.50) |
| 2000| 81.7%      | 27               | 14.3%         | 1.07         | (0.82-1.39) |
| 2250| 91.9%      | 33               | 14.2%         | 1.08         | (0.84-1.39) |
| 2447| 100.0%     | 41               | 13.2%         | 1.07         | (0.83-1.37) |

**Fig. 4** Effect of low vs. very low pressure on FLOW trial patients at different sample sizes
the FLOW trial in small increments. However, if investigators conduct repeated interim analyses during the course of a trial without adjusting the significance level, there is a very real risk of observing a significant result merely by chance [6]. To mitigate this risk, it is important that investigators follow established early stopping rules that require more stringent significance levels when conducting interim analyses.

There has been a recent focus on large RCTs among the orthopaedic community, as evident by the Orthopaedic Trauma Association’s decision to feature a symposium that only included the findings from large RCTs at their 2015 Annual Meeting. Different trial groups have been established (i.e. COTS, METRC, OTRC) with mandates of conducting large, multi-centre RCTs. Despite this shift, the orthopaedic literature continues to be dominated by studies that are underpowered to guide current evidence. While many readers understand that trials may be underpowered, few realize that truly erroneous conclusions may come from smaller studies, including a reversal of the initial findings. In a review of 47 highly cited research studies published in 3 high impact medical journals, Ioannidis found that of the 45 studies that claimed the intervention in question was effective, seven (16%) were contradicted by subsequent studies and seven others (16%) demonstrated effects that were stronger than those found in future studies [2]. Among the RCTs included in his review, those with contradicted or stronger effects were significantly smaller ($p = 0.009$) than those whose effects were either replicated by future studies or whose findings remained unchallenged by subsequent studies. Similar findings have been observed within the orthopaedic literature, in that trials with smaller sample sizes and lower event rates have been shown to observe larger treatment effects in their results [7]. Similar to our FLOW analysis, an analysis of data from the SPRINT trial [8] found a smaller sample size for the SPRINT trial would have led to misleading estimates of the relative risk of reoperation between reamed and unreamed nails in the management of closed tibial shaft fractures [3]. As demonstrated by the results of the review by Ioannidis, the SPRINT analysis, and the current analyses of the data from the FLOW trial, readers need to consider the adequacy of the sample size when reviewing the results of RCTs.

Specifically, readers should consider whether the sample size calculation was based upon realistic estimates of event rates and meaningful risk reductions. In addition, readers should consider whether the sample size calculation is based upon continuous outcomes (e.g. health related quality of life) or a dichotomous outcome (e.g. reoperation, mortality), as calculations using continuous outcomes require smaller sample sizes (often of 80 to 120 patients). Many studies within the orthopaedic trauma literature use continuous outcomes and have sample sizes of approximately 100 patients, which can be sensitive to the results of a few outlier patients [9].

Conclusions
In conclusion, the data presented from the FLOW study highlight the need for large clinical trials in the field of orthopaedic trauma. Researchers designing a clinical trial need to carefully calculate the sample size to ensure that meaningful results can be achieved to accurately guide clinical practice. Readers of the orthopaedic trauma literature need to critically evaluate the sample size justification as part of their decision to use clinical research to guide the care of their patients.

Abbreviations
95% CI: 95% confidence interval; COTS: Canadian Orthopaedic Trauma Society; FLOW: Fluid Lavage in Open Fracture Wounds; METRC: Major Extremity Trauma Research Consortium; OTRC: Orthopaedic Trauma Research Consortium; RCT: Randomized controlled trial; REB: Research Ethics Board; RR: Relative risk; SPRINT: Study to prospectively evaluate reamed intramedullary nails in patients with tibial fractures.

Acknowledgements

FLOOR Investigators:
Steering Committee: Mohit Bhandari (Chair, McMaster University), Gordon H. Guyatt (Co-Chair, McMaster University), Kyle J. Jeray (Co-Chair, Greenville Health System), Stephen Walter (McMaster University), Brad Petrisor (McMaster University), Emil H. Schemitsch (St. Michael’s Hospital), Paul Tornetta III (Boston University Medical Center), Jeff Anglen (Eisenkai Health Services, Indiana University), Michael Bosse (Carolinas Health Care System), Susan Liew (The Alfred), Parag Sancheti (Sancheti Institute for Orthopaedics and Rehabilitation).
Global Methods Centre: Mohit Bhandari (Principal Investigator); Sheila Sprague (Research Methodologist); Paula McKay, Kim Madden, Kerry Tai (Project Management); Diane Heells-Andsell, (Statistical Analysis); Lisa Buckingham, Aravin DuraiKannan (Data Management) (McMaster University).
United States Methods Centre: Kyle J. Jeray (Principal Investigator), Stephanie L. Tanner, Rebecca G. Snider (Project Management) (Greenville Health System).
Data Monitoring Committee: Douglas Altman (University of Oxford), Rajiv Gandhi (Toronto Western Hospital), Markus Bischoff (McMaster University).
Adjudication Committee: Mohit Bhandari (McMaster University), Gregory J. Della Rocca (University of Missouri Health Care), Brad Petrisor (McMaster University), Kyle J. Jeray (Greenville Health System), Emil H. Schemitsch (St. Michael’s Hospital).
Participating Clinical Sites:
Canada - Hamilton Health Sciences – Brad Petrisor, Bill Risteviski, Krishan Rajaratnam, Dale Williams, Matthew Denkers, Drew Bednar, John Sadler, Desmond Kwok, Mohit Bhandari, Brian Drew, Ivan Wong, Paula McKay, Kim Madden, Kerry Tai, St. Michael’s Hospital – Jeremy A. Hall, Michael D. McKee, Emil H. Schemitsch, Henry Ahn, Daniel Whelan, James Waddey, Timothy Daniels, Earl Bogoch, Aaron Nault, Milena R. Vicente, Jennifer T. Hidy. London Health Sciences Centre – David Sanders, Abdel-Rahman Lawvendy, Kevin Gurr, Timothy Carey, Chris Bailey, Mark Macleod, Debra Barley, Christina Tieszler, Queen Elizabeth II Health Sciences Centre – Chad Coles, Ross Leighton, C. Glen Richardson, Michael Bidulph, Michael Gross, Michael Dunbar, J. David Amirauid, David Alexander, Catherine Coady, Mark Glazebrook, David Johnston, William Oxner, J. Andrew Trenholm, Gerald Reardon, Kelly Trask, Shelley MacDonald. The Ottawa Hospital Civic Campus – Steven Papp, Wade Goffon, Allan Liew, Stephen Kingwell, Joseph O’Neill, Garth Johnson, Eugene Wai, Julia Foskall. Vancouver General Hospital – Henry M. Broekhuysen, Peter J. O’Brien, Pietr A. Blachut, Kelly A. Leaive, Raman J. Johal. Hôpital du Sacré-Cœur de Montréal – Stéphane Leduc, G. Yves Lafamme, Pierre Beaumont, Michel Malo, Benoît Benoît, Dominique Rouleau, Pierre Ranger, Julie Fournier, Karine Tartid. McGill University Health Centre – Rudy Reindl, Greg Berry, Edward Harvey, William Fisher, Mark Burman, Paul Martineau, Eric Lenczner, Robert Marien, Robert Turcotte, Michael Tanszer, Max Talbot, Peter Jarzem, Mike
Weber, Fiona Houghton. University of British Columbia/Fraser Health Authority – Robert McCormack, Kelly Apostle, Dorry Boyar, Farhad Moolad, Bertrand Perey, Trevor Stone, Darius Viskontas, H. Michael Lemke, Mauri Zornay, Karin Moon, Raely Moon. Sunnybrook Health Sciences Centre - Hans Kreder, Richard Jeppson, David Jenkins, Stephen Markkula Nousiainen, Tery Axelrod, Veronica Wadley, Michael Ford, Joel Finkelstein, Richard Saltz, Robin Richards, Sebastian Rodriguez-Elsalde, Diane Rahn, Albert Yee, Patrick Henry, John Marnaghan, Harsha Malempati, Julian Sernik, Tim Dwyer, Katrina Milner, Monica Kunz, Melanie MacNevin, Wesley Ghent, Faitha Adamsahibi, Ria De Gorter, Michelle Arakgi. Winnipeg Health Sciences Centre - Ted V. Tufescu, Brad Pilkey, Chris Graham, Laura Barron, Allan Hammond, Nigar Sultana. Queen's University – Ryan T. Buckell, David Pichora, Aaron Campbell, Fiona Howells. Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRUCH) – Annie Deshaies, Frédéric Balg, François Cabana, Rejane Dumas, Jean-François Jocens, Marc-André Magalhaes-Grave, Nicolas Patenaude, Bernard LaRue, Stéphane Ricard, Chantal Théorêt, François Vézina, Amy Stovelis, Jennifer Dawson, Hôpital de l'Enfant-Îles – Stéphane Pélet, Jean Lamontagne, Luc Bédard, Alexandre Demautel, Pierre Lavallée, Luc Pelletier, Bernard Laliberté, Martin Bédard, Marie-Eve Roger, Luc Lemire, Hélène Côté, Linda Lépine, Pascale Lévesque-Bernier.

United States - Greenville Health System – Kyle I. Jeray, John C. Broderick, David R. Goetz, Thomas M. Schaller, Scott E. Porter, Michael L. Beckish, John D. Adams Jr., Benjamin B. Barden, Grant W. Bennett, David M. Conner, Aaron T. Creek, Melissa M. Earles, Stephen H. Finley, Jonathan L. Forret, Garland K. Gudger Jr., Richard W. Gurich Jr., Austin D. Hill, S. Matthew Holtenbeck, Lyle T. Jackson, Benjamin S. Koch, Kevin K. Kruse, Wesley G. Lackey, Justin W. Lanigan, Julia Lee, Lauren C. Leffler, Michael J. Maughon Jr., S. Brennan McClure, Timothy J Miller, R. Lee Murphy Jr., Lawrence K. O'Malley, Dustin M. Price, Lorra M. Sharp, J. Adam Smitherman, John A. Tansley Jr., Erick G. Torres, Dylan J. Watson, Scott T. Watson, Stephanie L. Tanner, Rebecca G. Snider, Shea A. Belby, Lauren A. Nastoff, Robert J. Teasdale. United States Army Institute of Surgical Research and Brooke Army Medical Center – Joseph Hsu, Katherine M. Bedigian, Todd Gerlinger, Dave Brown, Joseph Alderete, Kevin Kirk, Mickey Cho, Anthony Johnson, Raymond Topp, Damian Rispoli, James Ficke, Eric Ritchie, Anthony Beardmore, Siraj Sayeed, Michael Chalton, Kristen Wallik, Dmitry Tudor, Greg Maytik, Travis Burns, Donald Gajewski, Warren Kaczmars, Ramon Andresen, Patrick Osborn, Michael Connally, Donna Lopez, Mary Fan, Dennis Mann, Andrea Garza, Rina L. Harman. Duke University Medical Center – Steven Olson, Robert Zura, Rachel Reilly, Preonna Patel, Claude T Moorman, Fraser Leveredge, Chard Harbour, Brian Brigman, David Ruch, Nikoletta Leonartitis, Michael Bolognesi, Shalini Ramasunder, Alison Toth, Allen Diane, Grant Garrigues, Dean Taylor, Richard C. Mather III, Kristoff Reid, Robert Lark, Samuel Adams, Maria Manson. San Francisco General Hospital – Utku Kandemir, Saam Meshrd, Murat Pekezic, Richard Coughlin, Trigg McClellan, Meir Marmor, Eric Meinberg, Tigist Belaye, Francois Cabana, Rejane Dumas, John Magne Høseth, Bernhard Flatøy, Havard Furunes, Peder Bogsti, Guri Eikås, Gilbert Moatshe, Ali Al-Shatiri, Tore Fjalestad, Fredrik Nilsen, Morten Smersdriis, Anne Christine Brekke, Elise Berg Vesterhus, Sissel Knuts. Sancheti Institute for Orthopaedics and Rehabilitation (India) – Parag Sancheti, Steve Rocha, Chetan Puram, Atul Patil, Neelam Jhangiani. Highway Hospital (India) – Anil K. Rai, Kamal Narayan Rai. Jabade Hospital (India) – Vivek V. Jabade, Deepali Nassikars. Karne Hospital (India) – Narayan J Karne, Chetan Metha. Apollo Hospital Tonderpert (India) – A Navaladi Shankar. Apollo Hospital Greens Lane (India) – A Navaladi Shankar, R Saravana. Nimal Hospital (India) – Ajay Gupta, Neera. Jain. RB Hospital and Research Centre (India) – Mahesh Bhatia, Vinod Arora, Vivek Tyagi, Anoop Dubey. Popular Hospital (India) – Vinod Yadav, Rani Rai. Kohphur Institute of Orthopaedics and Trauma (India) – Kian M. Doshi, Arjun Patil.

Funding
The FLOW trial was supported by Research Grants from the Canadian Institutes of Health Research # MCT-93173, United States Army Institute of Surgical Research, Orthopaedic Trauma Research Program (OTRP) and Peer Reviewed Orthopaedic Research Program (Pпор) and Association Internationale pour l’Ostéosynthèse Dynamique (AOID). Stryker Company provided Surgitav irrigators for the trial for clinical sites in Asia. Zimmer Company provided the Pulsavac irrigator at discounted rates to selected clinical sites in North America. Triad Medical donated the initial supply of castle soap for the study. No donor or funder had a role in the design or conduct of the FLOW study, data collection or analyses, or the preparation of this manuscript. The FLOW trial was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Orthopaedic Trauma Research Program under Award No. W81XWH-08-1-0473 and the Peer Reviewed Orthopaedic Research Program under Award No. W81XWH-12-1-0530. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MB, BP, and KJ were the principal investigators for the FLOW pilot and definitive trials, and were responsible for the conception of the current study. SS, GPS, and NNO participated in the design of the study, completed the data analyses, interpreted the results, and drafted the manuscript. PM provided input regarding the study design and participated in drafting of the manuscript. All authors reviewed the manuscript and provided critical input regarding its intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate
REB Approval for the FLOW pilot and definitive trial was obtained at the coordinating centre (McMaster University) (REB: 05-299 and 08-268) and at each clinical site. Informed consent was obtained from all participants prior to enrollment. All procedures followed were in accordance with ethical standards of the ethics boards.

Consent for publication
Not applicable.

Competing interests
SS reports grants from the Canadian Institutes of Health Research, employment/salary from McMaster University, and employment/salary from Global Research Solutions outside the submitted work. PIII reports other from Smith & Nephew and other from Lippincott Williams & Wilkins outside the submitted work. PM reports personal fees from Global Research.
Solutions outside the submitted work. BP reports grants from Stryker, outside the submitted work. KJJ reports personal fees from Zimmer, personal fees from Lilly USA, LLC, and personal fees from Pacira outside the submitted work. MB reports grants from Canadian Institutes of Health Research, other from Stryker, other from Zimmer, other from Triad Medical, grants from Office of the Assistant Secretary of Defense for Health Affairs through the Orthopaedic Trauma Research Program and the Peer Reviewed Orthopaedic Research Program, and grants from Association Internationale pour l’Osteosynthese Dynamique during the conduct of the study. He reports grants and personal fees from Stryker, personal fees from Smith & Nephew, grants and personal fees from Amgen, grants from DePuy, grants and personal fees from Eli Lilly, grants and personal fees from DJO Global Inc., personal fees from Zimmer, and personal fees from Ferring outside the submitted work. GPS, NNO, and DS have nothing to disclose.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, ON, Canada. 2 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
3 Department of Orthopaedic Surgery, Boston University School of Medicine, Boston, MA, USA. 4 Department of Orthopaedics, University of Maryland School of Medicine, R Adams Cowley Shock Trauma Center, Baltimore, MD, USA. 5 Department of Orthopaedic Surgery, Greenville Health System, Greenville, SC, USA. 6 Department of Surgery, University of Western Ontario, London, ON, Canada.

Received: 13 April 2017 Accepted: 27 March 2018
Published online: 20 April 2018

References
1. Hilibrand AS, Spindler K, O’Keefe RJ. Demonstrating the value of orthopaedic surgery through multicenter trials: AOA critical issues. J Bone Joint Surg Am. 2015;97:e35.
2. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:218–28.
3. SPRINT Investigators, Bhandari M, Tornetta P 3rd, Rampersad SA, Sprague S, Heels-Ansdell D, et al. (Sample) size matters! An examination of sample size from the SPRINT trial study to prospectively evaluate reamed intramedullary nails in patients with tibial fractures. J Orthop Trauma. 2013;27:183–8.
4. FLOW Investigators. Fluid lavage of open wounds (FLOW): design and rationale for a large, multicenter collaborative 2 x 3 factorial trial of irrigating pressures and solutions in patients with open fractures. BMC Musculoskelet Disord. 2010;11:85.
5. FLOW Investigators. A trial of wound irrigation in the initial management of open fracture wounds. N Engl J Med. 2015;373:2629–41.
6. Briel M, Bassler D, Wang AT, Guyatt GH, Montori VM. The dangers of stopping a trial too early. J Bone Joint Surg Am. 2012;94(Suppl 1):56–60.
7. Sung J, Siegel J, Tornetta P, Bhandari M. The orthopaedic trauma literature: an evaluation of statistically significant findings in orthopaedic trauma randomized trials. BMC Musculoskelet Disord. 2008;9:14.
8. SPRINT Investigators BM, Guyatt G, Tornetta P 3rd, Schemitsch E, Swiontkowski M, et al. Study to prospectively evaluate reamed intramedullary nails in patients with tibial fractures (S.P.R.I.N.T.): study rationale and design. BMC Musculoskelet Disord. 2008;9:91.
9. Lochner HV, Bhandari M, Tornetta P 3rd. Type-II error rates (beta errors) of randomized trials in orthopaedic trauma. J Bone Joint Surg Am. 2001;83-A:1650–5.